What is Sangamo Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sangamo Therapeutics's interest expense for the
three
months ended in Dec. 2023 was $ 0.0 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sangamo Therapeutics's Operating Income for the
three
months ended in Dec. 2023 was $ -61.8 Mil. Sangamo Therapeutics's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.0 Mil.
GuruFocus does not calculate Sangamo Therapeutics's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Sangamo Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sangamo Therapeutics (NAS:SGMO) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Sangamo Therapeutics's Interest Expense for the
three
months ended in Dec. 2023 was $0.0 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-61.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $33.5 Mil.
Sangamo Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| GuruFocus does not calculate Sangamo Therapeutics's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Sangamo Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
Sangamo Therapeutics (Sangamo Therapeutics) Business Description
Traded in Other Exchanges
Address
7000 Marina Boulevard, Brisbane, CA, USA, 94005
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.
Executives
| Biogen Inc. |
10 percent owner |
225 BINNEY STREET, CAMBRIDGE MA 02142 |
| Beers Courtney |
director |
C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005 |
| Margaret A Horn |
director |
925 PAGE MILL ROAD, PALO ALTO CA 94304 |
| Nathalie Dubois-stringfellow |
officer: SVP-Chief Development Officer |
C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005 |
| John Markels |
director |
C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804 |
| H Stewart Parker |
director |
|
| Biogen Ma Inc. |
10 percent owner |
225 BINNEY STREET, CAMBRIDGE MA 02142 |
| Scott B. Willoughby |
officer: SVP, Gen. Counsel & Secretary |
7000 MARINA BLVD, BRISBANE CA 94005 |
| Gary Loeb |
officer: EVP & General Counsel |
5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608 |
| Jason D. Fontenot |
officer: SVP, Chief Scientific Officer |
7000 MARINA BLVD, BRISBANE CA 94005 |
| Robert J. Schott |
officer: SVP, Head of Development |
7000 MARINA BLVD, BRISBANE CA 94005 |
| Rolf Andrew Ramelmeier |
officer: EVP, Technical Operations |
7000 MARINA BLVD, BRISBANE CA 94005 |
| Saira Ramasastry |
director |
501 CANAL BLVD., RICHMOND CA 94804 |
| Kenneth J. Hillan |
director |
C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080 |
| David Mark Mcclung |
officer: EVP Chief Business Officer |
7000 MARINA BLVD, BRISBANE CA 94005 |
Sangamo Therapeutics (Sangamo Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGMO has been successfully added to your 